This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
by Zacks Equity Research
Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
by Zacks Equity Research
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
by Zacks Equity Research
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIDI
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
by Zacks Equity Research
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
Why Is Jazz (JAZZ) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
by Zacks Equity Research
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
by Zacks Equity Research
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity. Stiff competition in the target market is a woe.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Wall Street Analysts Believe Jazz (JAZZ) Could Rally 56.66%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 56.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Jazz Pharmaceuticals (JAZZ) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
Investing in Jazz (JAZZ)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
by Zacks Equity Research
Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 13.25% and 2.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Investors need to pay close attention to JAZZ Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
by Zacks Equity Research
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.